Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study
Circulation · 10.01.2023 · 147 (2) · 108-117
DOI: 10.1161/circulationaha.122.062770 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 10.01.2023. Verfasst von Jeehoon Kang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Seoul National University Hospital, Korea (J.K., K.W.P., H.L., D.H., H.-M.Y., J.-K.H., B.-K.K., H.-S.K.). Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Myocardial Infarction, Percutaneous Coronary Intervention, Thrombosis. Die Arbeit wurde bisher 161-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Ministry of Health and Welfare, Seoul National University Hospital.
Abstract (Originalsprache)
Background
Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Extended Antiplatelet Monotherapy) Extended study reports the posttrial follow-up results of the original HOST-EXAM trial.
Methods
From March 2014 through May 2018, 5438 patients who maintained dual antiplatelet therapy without clinical events for 12±6 months after percutaneous coronary intervention with drug-eluting stents were randomly assigned in a 1:1 ratio to receive clopidogrel (75 mg once daily) or aspirin (100 mg once daily). The primary end point (a composite of all-cause death, nonfatal myocardial infarction, stroke, readmission attributable to acute coronary syndrome, and Bleeding Academic Research Consortium type 3 or greater bleeding), secondary thrombotic end point (cardiac death, nonfatal myocardial infarction, ischemic stroke, readmission attributable to acute coronary syndrome, and definite or probable stent thrombosis), and bleeding end point (Bleeding Academic Research Consortium type 2 or greater bleeding) were analyzed during the extended follow-up period. Analysis was performed on the per-protocol population (2431 patients in the clopidogrel group and 2286 patients in the aspirin group).
Results
During a median follow-up of 5.8 years (interquartile range, 4.8–6.2 years), the primary end point occurred in 12.8% and 16.9% in the clopidogrel and aspirin groups, respectively (hazard ratio, 0.74 [95% CI, 0.63–0.86]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Seoul National University Hospital, Korea (J.K., K.W.P., H.L., D.H., H.-M.Y., J.-K.H., B.-K.K., H.-S.K.).
- Korea University Guro Hospital, Seoul, Korea (S.-W.R.).
- Chungbuk National University, Cheongju, Korea (J.-W.B.).
- Kangnam Sacred Heart Hospital, Hallym University, Seoul, Korea (N.H.L.).
- Keimyung University Dongsan Hospital, Daegu, Korea (S.-H.H.).
- Ulsan University Hospital, Korea (E.-S.S.).
ORCID-Profile: Kyung Woo Park, Doyeon Hwang, Han-Mo Yang, Jang-Whan Bae, Jung-Kyu Han, Eun-Seok Shin, Bon-Kwon Koo, Hyo-Soo Kim
Förderung
- Ministry of Health and Welfare
- Seoul National University Hospital
Zitieren
APA
Kang, J., Park, K. W., Lee, H., Hwang, D., Yang, H. M., Rha, S. W., Bae, J. W., Lee, N. H., Hur, S. H., Han, J. K., Shin, E. S., Koo, B. K., & Kim, H. S. (2023). Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study. Circulation, 147(2), 108-117. https://doi.org/10.1161/circulationaha.122.062770
Vancouver
Kang J, Park KW, Lee H, Hwang D, Yang HM, Rha SW, et al. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study. Circulation. 2023;147(2):108-117. doi:10.1161/circulationaha.122.062770
BibTeX
@article{Kang2023,
author = {Kang, Jeehoon and Park, Kyung Woo and Lee, Huijin and Hwang, Doyeon and Yang, Han-Mo and Rha, Seung-Woon and Bae, Jang-Whan and Lee, Nam Ho and Hur, Seung-Ho and Han, Jung-Kyu and Shin, Eun-Seok and Koo, Bon-Kwon and Kim, Hyo-Soo},
title = {Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study},
journal = {Circulation},
year = {2023},
volume = {147},
number = {2},
pages = {108--117},
doi = {10.1161/circulationaha.122.062770}
}
EUVIMED